Z
Zentalis Pharmaceuticals
Biotech & Life Sciences · San Diego, United States · Founded 2014 · IPO 2020
Clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics MoreLess
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapeutics for cancer treatment. The company operates in the oncology sector, targeting fundamental biological pathways of cancers to create clinically differentiated therapies. Zentalis primarily serves patients suffering from various forms of cancer, including advanced non-Hodgkin lymphoma and acute myeloid leukemia. The company's business model revolves around its Integrated Discovery Engine, which efficiently identifies and develops novel oncology therapies by focusing on clinically validated and commercially proven targets. Zentalis generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. The company aims to improve patient outcomes and make a lasting impact on the field of oncology.
Keywords: oncology, biopharmaceutical, cancer treatment, small molecule therapeutics, clinical-stage, drug discovery, Integrated Discovery Engine, non-Hodgkin lymphoma, acute myeloid leukemia, patient outcomes.
Company overview
Zentalis Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- San Diego, United States
- Employees
- 121
- Open positions
- 11
- Dealroom signal
- 65.9
Valuation & funding
Zentalis Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2023 | $250M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Apr 2022 | $25M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Aug 2021 | $75M | $865M | OrbiMed · Lilly Asia Ventures · Logos Capital · Avidity Partners | — |
| SECONDARYOther financing | Jul 2021 | $173M | — | Undisclosed | — |
| POST IPO EQUITYOther financing | May 2020 | $20M | — | Tybourne Capital Management · OrbiMed | — |
| IPOOther financing | Apr 2020 | Undisclosed | ↗ | ||
| SERIES COther financing | Dec 2019 | Viking Global Investors · Redmile Group · Eventide Asset Management · Perceptive Advisors | — | ||
| SERIES BOther financing | Dec 2017 | Viking Global Investors · Matrix Capital | — | ||
| SERIES BOther financing | Jan 2017 | Pharmaron Holding · Viking Global Investors · Alexandria Equities · Mayo Clinic | — | ||
| SERIES AOther financing | Mar 2016 | Pharmaron Holding · Mayo Clinic · Viking Global Investors · Alexandria Equities | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$153M | — |
| 2025 | $0 | -100% | −$153M | — |
| 2024 | $67M | — | −$208M | -308.4% |
| 2023 | $0 | — | −$230M | — |
| 2022 | $0 | — | −$233M | — |
| 2021 | $0 | — | −$269M | — |
| 2020 | $0 | — | −$119M | — |
Growth signals
Zentalis Pharmaceuticals website traffic
Latest recorded traffic for Zentalis Pharmaceuticals is 6.5K monthly website visits, down 33.7% over the last three months. Zentalis Pharmaceuticals's team declined 3.2% over the past year.
Hiring
Open positions at Zentalis Pharmaceuticals
Current openings linked to this company in Dealroom.
Comparisons
Zentalis Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Zentalis Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Zentalis Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about Zentalis Pharmaceuticals
Recent press, funding announcements, and product moves mentioning Zentalis Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Zentalis Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Zentalis Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zentalis Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.